Compare Coinbase Global, Inc. (COIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Merck & Co., Inc. — how do they compare? Coinbase Global, Inc. trades at $181.34 (market cap $45.38B), while Merck & Co., Inc. trades at $144.97 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.7× Coinbase Global, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Merck & Co., Inc. for 98 Days on average.
| COIN | MRK | |
|---|---|---|
Market Cap | $45.38B | $351.28B |
Volume | 11,013,940 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $387.00 | $156.43 |
52-Week Low | $141.09 | $82.49 |
Typical Hold Time | 78 Days | 98 Days |
Enterprise Value | $43.03B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $178.45, down 3.92% in 24 hours, with a bearish technical signal and support near $173. The company reported revenue of $7.18B in 2025 with a net income of $1.26B, though recent quarters have missed EPS expectations. Positive developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup, driving institutional optimism.
The stock presents a mixed outlook: analyst consensus is bullish with a $211.55 price target, but high valuation ratios and volatile earnings pose risks. Regulatory scrutiny and crypto market dependence remain key concerns for sustained growth.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
